Beigene Ltd (BGNE)

$184.84

+1.88

(+1.03%)▲

Market is closed - opens 8 PM, 29 Nov 2023

Insights on Beigene Ltd

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 380.09M → 781.30M (in $), with an average increase of 21.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -381.13M → 215.41M (in $), with an average increase of 276.9% per quarter

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 82.5% return, outperforming this stock by 79.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 26.6% return, outperforming this stock by 61.9%

Performance

  • $181.59
    $184.85
    $184.84
    downward going graph

    1.76%

    Downside

    Day's Volatility :1.76%

    Upside

    0.01%

    downward going graph
  • $156.56
    $280.62
    $184.84
    downward going graph

    15.3%

    Downside

    52 Weeks Volatility :44.21%

    Upside

    34.13%

    downward going graph

Returns

PeriodBeigene LtdSector (Health Care)Index (Russel 2000)
3 Months
-13.46%
-3.9%
0.0%
6 Months
-22.38%
1.7%
0.0%
1 Year
2.77%
-4.5%
-3.7%
3 Years
-27.71%
18.5%
-4.7%

Highlights

Market Capitalization
19.9B
Book Value
$36.16
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-9.24
PEG Ratio
0.0
Wall Street Target Price
286.55
Profit Margin
-43.53%
Operating Margin TTM
-17.15%
Return On Assets TTM
-13.2%
Return On Equity TTM
-22.8%
Revenue TTM
2.2B
Revenue Per Share TTM
21.13
Quarterly Revenue Growth YOY
101.6%
Gross Profit TTM
-511.1M
EBITDA
-1.2B
Diluted Eps TTM
-9.24
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-8.03
EPS Estimate Next Year
-8.32
EPS Estimate Current Quarter
-3.09
EPS Estimate Next Quarter
-3.07

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Beigene Ltd(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
13
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 55.03%

Current $184.84
Target $286.55

Company Financials

FY17Y/Y Change
Revenue
238.4M
↑ 22179.16%
Net Income
-93.1M
↓ 21.9%
Net Profit Margin
-39.06%
↑ 11102.72%
FY18Y/Y Change
Revenue
198.2M
↓ 16.85%
Net Income
-673.8M
↑ 623.67%
Net Profit Margin
-339.91%
↓ 300.85%
FY19Y/Y Change
Revenue
428.2M
↑ 116.03%
Net Income
-950.6M
↑ 41.08%
Net Profit Margin
-221.99%
↑ 117.92%
FY20Y/Y Change
Revenue
308.9M
↓ 27.87%
Net Income
-1.6B
↑ 68.37%
Net Profit Margin
-518.18%
↓ 296.19%
FY21Y/Y Change
Revenue
1.2B
↑ 280.83%
Net Income
-1.4B
↓ 11.69%
Net Profit Margin
-120.15%
↑ 398.03%
FY22Y/Y Change
Revenue
1.4B
↑ 20.37%
Net Income
-2.0B
↑ 41.78%
Net Profit Margin
-141.52%
↓ 21.37%
Q2 FY22Q/Q Change
Revenue
341.6M
↑ 11.4%
Net Income
-571.4M
↑ 31.59%
Net Profit Margin
-167.3%
↓ 25.67%
Q3 FY22Q/Q Change
Revenue
387.6M
↑ 13.48%
Net Income
-557.6M
↓ 2.43%
Net Profit Margin
-143.84%
↑ 23.46%
Q4 FY22Q/Q Change
Revenue
380.1M
↓ 1.94%
Net Income
-445.3M
↓ 20.13%
Net Profit Margin
-117.16%
↑ 26.68%
Q1 FY23Q/Q Change
Revenue
447.8M
↑ 17.81%
Net Income
-348.4M
↓ 21.76%
Net Profit Margin
-77.81%
↑ 39.35%
Q2 FY23Q/Q Change
Revenue
595.3M
↑ 32.93%
Net Income
-381.1M
↑ 9.39%
Net Profit Margin
-64.03%
↑ 13.78%
Q3 FY23Q/Q Change
Revenue
781.3M
↑ 31.25%
Net Income
215.4M
↓ 156.52%
Net Profit Margin
27.57%
↑ 91.6%
FY17Y/Y Change
Total Assets
1.0B
↑ 157.87%
Total Liabilities
362.2M
↓ 10.74%
FY18Y/Y Change
Total Assets
2.2B
↑ 114.98%
Total Liabilities
496.0M
↑ 36.93%
FY19Y/Y Change
Total Assets
1.6B
↓ 28.33%
Total Liabilities
633.9M
↑ 27.8%
FY20Y/Y Change
Total Assets
5.6B
↑ 247.38%
Total Liabilities
1.7B
↑ 173.14%
FY21Y/Y Change
Total Assets
8.6B
↑ 54.37%
Total Liabilities
2.4B
↑ 38.78%
FY22Y/Y Change
Total Assets
6.4B
↓ 26.22%
Total Liabilities
2.0B
↓ 16.94%
Q2 FY22Q/Q Change
Total Assets
7.4B
↓ 8.02%
Total Liabilities
2.1B
↓ 2.82%
Q3 FY22Q/Q Change
Total Assets
6.7B
↓ 8.84%
Total Liabilities
2.1B
↓ 0.23%
Q4 FY22Q/Q Change
Total Assets
6.4B
↓ 5.15%
Total Liabilities
2.0B
↓ 3.62%
Q1 FY23Q/Q Change
Total Assets
6.0B
↓ 6.62%
Total Liabilities
1.8B
↓ 9.84%
Q2 FY23Q/Q Change
Total Assets
5.7B
↓ 3.83%
Total Liabilities
1.9B
↑ 7.26%
Q3 FY23Q/Q Change
Total Assets
5.5B
↓ 3.56%
Total Liabilities
1.8B
↓ 8.73%
FY17Y/Y Change
Operating Cash Flow
12.8M
↓ 114.25%
Investing Cash Flow
-356.3M
↑ 60.61%
Financing Cash Flow
490.4M
↑ 28.74%
FY18Y/Y Change
Operating Cash Flow
-547.7M
↓ 4395.15%
Investing Cash Flow
-637.6M
↑ 78.94%
Financing Cash Flow
1.7B
↑ 244.76%
FY19Y/Y Change
Operating Cash Flow
-750.3M
↑ 36.98%
Investing Cash Flow
554.2M
↓ 186.91%
Financing Cash Flow
85.7M
↓ 94.93%
FY20Y/Y Change
Operating Cash Flow
-1.3B
↑ 71.07%
Investing Cash Flow
-3.2B
↓ 671.74%
Financing Cash Flow
5.2B
↑ 5972.39%
FY21Y/Y Change
Operating Cash Flow
-1.3B
↑ 1.19%
Investing Cash Flow
640.7M
↓ 120.22%
Financing Cash Flow
3.6B
↓ 30.1%
Q2 FY22Q/Q Change
Operating Cash Flow
-380.0M
↑ 60.62%
Investing Cash Flow
658.7M
↑ 213.09%
Financing Cash Flow
-17.6M
↑ 56.03%
Q3 FY22Q/Q Change
Operating Cash Flow
-561.9M
↑ 47.89%
Investing Cash Flow
169.5M
↓ 74.27%
Financing Cash Flow
120.2M
↓ 783.97%

Technicals Summary

Sell

Neutral

Buy

Beigene Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Beigene Ltd
Beigene Ltd
-0.95%
-22.38%
2.77%
-27.71%
28.44%
Moderna, Inc.
Moderna, Inc.
5.55%
-37.86%
-54.85%
-48.81%
320.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.02%
9.96%
8.84%
55.25%
122.81%
Novo Nordisk A/s
Novo Nordisk A/s
5.22%
26.94%
67.17%
202.19%
341.77%
Seagen, Inc.
Seagen, Inc.
0.0%
10.39%
82.47%
25.75%
240.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.91%
6.68%
9.71%
52.38%
93.39%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Beigene Ltd
Beigene Ltd
NA
NA
0.0
-8.03
-0.23
-0.13
0.0
36.16
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-11.52
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.78
22.78
9.01
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
43.04
43.04
2.03
2.62
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.52
26.52
0.41
15.04
0.23
0.14
0.02
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Beigene Ltd
Beigene Ltd
Buy
$19.9B
28.44%
NA
-43.53%
Moderna, Inc.
Moderna, Inc.
Buy
$29.6B
320.32%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$87.0B
122.81%
22.78
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$470.4B
341.77%
43.04
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.0B
240.59%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.0B
93.39%
26.52
35.94%

Institutional Holdings

  • Baker Bros Advisors LP

    11.02%

  • Capital Research & Mgmt Co - Division 3

    5.71%

  • Hillhouse Capital Advisors, Ltd.

    4.89%

  • PRIMECAP Management Company

    4.73%

  • Baillie Gifford & Co Limited.

    3.66%

  • Temasek Holdings Ltd.

    2.85%

Corporate Announcements

  • Beigene Ltd Earnings

    Beigene Ltd’s price-to-earnings ratio stands at None

    Read More

Company Information

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Organization
Beigene Ltd
Employees
10000
CEO
Mr. John V. Oyler
Industry
Health Technology

Discover More

FAQs